David Hallal is a 30-year veteran in the biopharmaceutical industry with expertise in early-stage company building as well as operating large multinational biotech companies. He also is Chairman of AlloVir.
by
Dr. Mitchell Finer serves as a Strategic Advisor for ElevateBio and will focus on supporting the organization as the Company accelerates and expands the first genetic medicines foundry. He is a co-founder of ElevateBio and previously served as the Company’s President of Research & Development and as Chief Executive Officer of Life Edit Therapeutics, ElevateBio’s gene editing business. Additionally, Dr. Finer is an executive partner at MPM Capital.
Vikas Sinha brings more than 25 years of experience in executive finance roles in the life sciences industry. He is Chief Financial Officer and co-founder of ElevateBio and also serves as President and Chief Financial Officer of AlloVir.
Jacob Abrams joined ElevateBio in 2020, and as general counsel, he leads the Company’s legal function.
Bhakti has over 15 years of experience in biotech, consulting, and financial services including corporate finance, business development, strategy, and business process re-engineering.
Tedd leads the scientific development of the Life Edit Therapeutics gene editing platform. He has more than 20 years of biotech experience focused on gene expression and pharmaceutical discovery and was previously Chief Scientific Officer at LifeEDIT Inc. when the company was a subsidiary of AgBiome.
Catherine Hu joined ElevateBio in 2021 to lead the Company’s investor relations and corporate affairs functions. Prior to ElevateBio, Catherine led investor relations, corporate affairs, and patient advocacy functions at Scholar Rock, Inc. and was part of the investor relations team at Alexion Pharmaceuticals.
Katie Jorgensen joined ElevateBio in 2021 and as Site Head at BaseCamp, she is responsible for supply chain, facilities, technical operations, manufacturing, and program management supporting strategic contracts and valued partnerships bringing innovative cell and gene therapies to patients. Previously, she was the Company’s VP, Commercial Operations and CMC Program Management.
Tess Kitchener has twenty years of experience in biotech, with the majority in CMC leadership roles, including those in process development, manufacturing technical support, and manufacturing. Currently, Tess is leading the BaseCamp Commercial team and is responsible for Business Development, Marketing and Commercial Operations for BaseCamp.
Missy has more than 15 years of experience in operations and people strategies. As a strategic thought partner to the leadership team, she identifies areas for operational improvement, provides insight and analysis on company strategy and operations, and ensures a continued focus on top priorities across the company.
Clare leads corporate development and operations at Life Edit Therapeutics. She has more than 20 years of pharmaceutical industry experience focused on drug discovery and business development and previously ran business development at LifeEDIT Inc., when the company was a subsidiary of AgBiome.
Aaron Nudelman joined ElevateBio in 2020, and as SVP, Head of Intellectual Property, he leads the Company’s IP function overseeing patent preparation, prosecution, maintenance, and enforcement; IP diligence and strategy; and IP aspects of license negotiation and related transactions.
